The number of people diagnosed with thyroid cancer is increasing -- one of the few cancers for which this is still the case. But a subset of these patients may be getting overdiagnosed with cancer.
In work that could improve understanding of how cancer spreads, a team of engineers and medical researchers at the University of Michigan developed a new kind of microfluidic chip that can capture rare, aggressive cancer cells, grow them on the chip and release single cells on demand.
Researchers at Michigan Medicine have found a protein that stops cancer’s ability to prevent the immune system from destroying cancer cells. The protein is called free C3d, and it has the potential to be developed into a cancer vaccine and a cancer treatment.
Can your phone make you healthier? That’s what researchers at the University of Michigan are hoping to find out.
U of M Faculty Identifies Clustering of Esophageal Cancer Mortality in the Great Lakes States and New England
Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Despite the rates of some cancers falling over the past 25 years, the frequency of some esophageal cancers is growing and physicians are unable to explain why.
New, statistically derived guidelines are helping urologists across Michigan zero in on which prostate cancer patients to scan for spread of their disease.
In celebration of National Nurses Week, we take time to honor the men and women who provide extraordinary patient care at Michigan Medicine.
A large study shows bone complications in thyroid cancer are an indicator of a poor prognosis, suggesting the need for more drug research.
University of Michigan Comprehensive Cancer Center experts will discuss breast cancer risks (and how you can reduce yours), as well as screening, treatment and research at a free Breast Cancer Summit on Saturday, May 6, 2017.
Physicians’ misunderstanding of genetic test results may hamper mastectomy decisions for breast cancer patients
A recent survey of over 2,000 women newly diagnosed with breast cancer found that half of those who undergo bilateral mastectomy after genetic testing don’t actually have mutations known to confer increased risk of additional cancers.